Please login to the form below

Not currently logged in
Email:
Password:

Suzanne Gagnon joins Idis as CMO

She was formerly chief medical officer at Icon

Idis Suzanne GagnonIdis has appointed Dr Suzanne Gagnon as its first chief medical officer.

Dr Gagnon will lead global medical affairs at Idis, which specialises in partnering with pharma firms to support patient access to medicines.

She was most recently chief medical officer at neuroscience company NuPathe, prior to which she spent ten years as chief medical officer at the clinical research organisation (CRO) Icon,

During her time at Icon, she gained senior level experience in medical, regulatory and clinical research operations, overseeing a staff of 400 professionals across 10 global locations.

"Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programmes that balance stakeholder requirements and effectively address the needs of patients," said Natalie Douglas, CEO of Idis. 

In addition to her industry experience, Dr Gagnon is adjunct professor, pharmaceutical product development at West Chester University, Pennsylvania.

13th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics